Sudeep Pharma Limited

Sudeep Pharma reported a strong H1 FY26 with total income growing 31% YoY to INR 302.9 crores and EBITDA increasing 21% YoY to INR 114.7 crores. However, the EBITDA margin for H1 FY26 was 37.9%, down from 40.9% in H1 FY25. For Q2 FY26, total income grew 15% YoY to INR 172.8 crores, but PAT declined by 3.89% YoY to INR 46.8 crores. The company attributed the Q2 performance to strategic investments and the impact of US tariffs, which caused some sales to shift to Q3.

The company operates through two primary verticals: pharmaceutical, food, and nutrition, which contributed 40% of H1 FY26 revenue, and specialty ingredients, contributing 60%. Sudeep Pharma emphasizes its technology-led approach, proprietary technologies like encapsulation and spray drying, and strong regulatory compliance, including USFDA approval and European CEP certification for calcium carbonate as an API. These capabilities differentiate Sudeep in specialized segments like infant and clinical nutrition where performance consistency is critical.

Sudeep Pharma serves customers in nearly 100 countries, with regional sales offices in the US and Europe. The company acquired an 85% stake in Nutrition Supplies and Services (NSS) in May 2025, an Ireland-based company specializing in infant and medical nutrition premixes. NSS contributed approximately INR 20 crores to Q2 revenue and operates at a ~30% EBITDA margin. This acquisition allows Sudeep to access European infant and clinical nutrition markets more rapidly and leverage its existing customer relationships.

The company is expanding its manufacturing footprint with a new greenfield facility in Nandesari, Gujarat, expected to be commissioned in Q4 FY26, with a total outlay of INR 150 crores, of which INR 120 crores was spent by September 2025. This facility will enhance capacity and meet stringent regulatory requirements. Additionally, Sudeep Pharma is building a greenfield manufacturing facility in Dahej for its Sudeep Advanced Materials (SAM) segment, with phase one capex of INR 220 crores for 25,000 metric tons capacity, targeted for completion by early 2027. The total capex for SAM to reach 100,000 tons capacity is estimated at INR 500 crores.

Sudeep Pharma has entered the high-growth battery material segment with Sudeep Advanced Materials (SAM), focusing on precursor cathode-active materials like battery-grade iron phosphate for LFP batteries. This diversification leverages the company's mineral chemistry expertise. SAM has received early validation from global customers, and its strategic positioning aims to address evolving regulatory restrictions and create a secure, ex-China supply chain. Initial revenue contribution from SAM is expected in FY28, following the commissioning of the Dahej facility.

The company consistently invests around 2% of its revenue in R&D, with three dedicated R&D facilities and 41 scientists. This focus enables the development of engineered minerals and ingredients for improved functional outcomes, such as increased absorption and enhanced shelf life. R&D is particularly critical for specialty ingredients and the new battery materials segment, ensuring innovation aligns with customer requirements and commercial scalability.

As of September 30, 2025, the company's net debt stood at INR 73 crores, with a conservative net debt to equity ratio of 0.1x. The working capital days were elevated at 195 days due to strategic inventory buildup for anticipated growth and the NSS acquisition. Management expects the working capital cycle to normalize to approximately 140-150 days in the medium term, and debt levels are projected to remain stable, with capex funded through internal accruals.